GB0305024D0 - Compounds - Google Patents
CompoundsInfo
- Publication number
- GB0305024D0 GB0305024D0 GBGB0305024.2A GB0305024A GB0305024D0 GB 0305024 D0 GB0305024 D0 GB 0305024D0 GB 0305024 A GB0305024 A GB 0305024A GB 0305024 D0 GB0305024 D0 GB 0305024D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- sub
- alkyl
- alkoxy
- haloc
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R<SUB>1 </SUB>is hydrogen, fluoro, chloro, hydroxy, C<SUB>1-6</SUB>alkyl, C<SUB>3-7</SUB>cycloalkyl, C<SUB>3-7</SUB>cycloalkyloxy, C<SUB>1-6</SUB>alkoxy or haloC<SUB>1-6</SUB>alkoxy; m is 0 when - is a double bond and m is 1 when - is a single bond; R<SUB>2 </SUB>is hydrogen, halogen, cyano, nitro, C<SUB>1-6</SUB>alkyl, C<SUB>3-7</SUB>cycloalkyl, C<SUB>3-7</SUB>cycloalkyloxy, haloC<SUB>1-6</SUB>alkyl, C<SUB>1-6</SUB>alkoxy, haloC<SUB>1-6</SUB>alkoxy, C<SUB>1-6</SUB>alkylthio, amino, mono- or di-C<SUB>1-6</SUB>alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is -(CH<SUB>2</SUB>-CH<SUB>2</SUB>)-, -(CH-CH)-, -(CH<SUB>2</SUB>)<SUB>3</SUB>-, -C(CH<SUB>3</SUB>)<SUB>2</SUB>-, -(CH-CH-CH<SUB>2</SUB>)-, -(CH<SUB>2</SUB>-CH-CH)- or a group -(CHR<SUB>5</SUB>)- wherein R<SUB>5 </SUB>is hydrogen, halogen, hydroxy, cyano, nitro, C<SUB>1-6</SUB>alkyl, C<SUB>3-7</SUB>cycloalkyl, C<SUB>3-7</SUB>cycloalkyloxy, haloC<SUB>1-6</SUB>alkyl, C<SUB>1-6</SUB>alkoxy, haloC<SUB>1-6</SUB>alkoxy or C<SUB>1-6</SUB>alkylthio; R<SUB>3 </SUB>is halogen, cyano, C<SUB>1-6</SUB>alkyl, C<SUB>3-7</SUB>cycloalkyl, C<SUB>3-7</SUB>cycloalkyloxy, C<SUB>1-6</SUB>alkoxy, C<SUB>1-6</SUB>alkylthio, hydroxy, amino, mono- or di-C<SUB>1-6</SUB>alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC<SUB>1-6</SUB>alkyl, haloC<SUB>1-6</SUB>alkoxy, aryl, arylC<SUB>1-6</SUB>alkyl, arylC<SUB>1-6</SUB>alkyloxy, arylC<SUB>1-6</SUB>alkylthio or COOR<SUB>6</SUB>, CONR<SUB>7</SUB>R<SUB>8 </SUB>or COR<SUB>9 </SUB>wherein R<SUB>6</SUB>, R<SUB>7</SUB>, R<SUB>8 </SUB>and R<SUB>9 </SUB>are independently hydrogen or C<SUB>1-6</SUB>alkyl; p is 0, 1 or 2 or 3; R<SUB>4 </SUB>is hydrogen, halogen, hydroxy, cyano, nitro, C<SUB>1-6</SUB>alkyl, C<SUB>1-6</SUB>alkanoyl, C<SUB>3-7</SUB>cycloalkyl, C<SUB>3-7</SUB>cycloalkyloxy, haloC<SUB>1-6</SUB>alkyl, C<SUB>1-6</SUB>alkoxy, haloC<SUB>1-6</SUB>alkoxy, C<SUB>1-6</SUB>alkylthio, amino, mono- or di-C<SUB>1-6</SUB>alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, -CH<SUB>2</SUB>- or NR<SUB>10 </SUB>wherein R<SUB>10 </SUB>is hydrogen or C<SUB>1-6</SUB>alkyl; D is a single bond, -CH<SUB>2</SUB>-, -(CH<SUB>2</SUB>)<SUB>2</SUB>- or -CH-CH-; and Z is -NR<SUB>11</SUB>R<SUB>12 </SUB>where R<SUB>11 </SUB>and R<SUB>12 </SUB>are independently hydrogen or C<SUB>1-6</SUB>alkyl, or an optionally substituted N-linked or C-linked 4 to 7 membered heterocyclic group. Method of preparation and uses of the compounds in therapy, for example depression and anxiety, are also disclosed.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0305024.2A GB0305024D0 (en) | 2003-03-05 | 2003-03-05 | Compounds |
DE602004012842T DE602004012842T2 (en) | 2003-03-05 | 2004-02-24 | AM 5HT2C RECEPTOR ACTIVE COMPOUNDS AND ITS USES |
EP04713874A EP1599445B1 (en) | 2003-03-05 | 2004-02-24 | Compounds having activity at 5ht2c receptor and uses thereof |
ES04713874T ES2304605T3 (en) | 2003-03-05 | 2004-02-24 | COMPOUNDS THAT HAVE ACTIVITY IN THE 5HT2C RECEIVER AND ITS USES. |
JP2006504465A JP2006519241A (en) | 2003-03-05 | 2004-02-24 | Compounds having 5-HT2C receptor activity and uses thereof |
AT04713874T ATE391121T1 (en) | 2003-03-05 | 2004-02-24 | COMPOUNDS ACTIVE ON 5HT2C RECEPTOR AND THEIR USES |
PCT/EP2004/001843 WO2004078718A1 (en) | 2003-03-05 | 2004-02-24 | Compounds having activity at 5ht2c receptor and uses thereof |
US10/548,118 US20060205788A1 (en) | 2003-03-05 | 2004-02-24 | Compounds having activity at 5ht2c receptor and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0305024.2A GB0305024D0 (en) | 2003-03-05 | 2003-03-05 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0305024D0 true GB0305024D0 (en) | 2003-04-09 |
Family
ID=9954160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0305024.2A Ceased GB0305024D0 (en) | 2003-03-05 | 2003-03-05 | Compounds |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060205788A1 (en) |
EP (1) | EP1599445B1 (en) |
JP (1) | JP2006519241A (en) |
AT (1) | ATE391121T1 (en) |
DE (1) | DE602004012842T2 (en) |
ES (1) | ES2304605T3 (en) |
GB (1) | GB0305024D0 (en) |
WO (1) | WO2004078718A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
US20050203079A1 (en) * | 2002-04-19 | 2005-09-15 | Glaxo Group Limited | Compounds having affinity at 5ht2C receptor and use thereof in therapy |
EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
JP5528699B2 (en) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | Fused heterocyclic compounds and uses thereof |
EP1935886A1 (en) * | 2006-12-22 | 2008-06-25 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
TW200840566A (en) * | 2006-12-22 | 2008-10-16 | Esteve Labor Dr | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
EP2510949A4 (en) | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | Therapeutic agent for fibromyalgia |
JPWO2019131902A1 (en) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | Remedies for stress urinary incontinence and fecal incontinence |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9612885D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
ATE420862T1 (en) * | 2000-06-12 | 2009-01-15 | Eisai R&D Man Co Ltd | 1,2-DIHYDROPYRIDINE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
US20050203079A1 (en) * | 2002-04-19 | 2005-09-15 | Glaxo Group Limited | Compounds having affinity at 5ht2C receptor and use thereof in therapy |
-
2003
- 2003-03-05 GB GBGB0305024.2A patent/GB0305024D0/en not_active Ceased
-
2004
- 2004-02-24 ES ES04713874T patent/ES2304605T3/en not_active Expired - Lifetime
- 2004-02-24 WO PCT/EP2004/001843 patent/WO2004078718A1/en active IP Right Grant
- 2004-02-24 US US10/548,118 patent/US20060205788A1/en not_active Abandoned
- 2004-02-24 EP EP04713874A patent/EP1599445B1/en not_active Expired - Lifetime
- 2004-02-24 DE DE602004012842T patent/DE602004012842T2/en not_active Expired - Fee Related
- 2004-02-24 JP JP2006504465A patent/JP2006519241A/en active Pending
- 2004-02-24 AT AT04713874T patent/ATE391121T1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2304605T3 (en) | 2008-10-16 |
WO2004078718A8 (en) | 2005-05-26 |
ATE391121T1 (en) | 2008-04-15 |
DE602004012842D1 (en) | 2008-05-15 |
WO2004078718A1 (en) | 2004-09-16 |
EP1599445A1 (en) | 2005-11-30 |
US20060205788A1 (en) | 2006-09-14 |
DE602004012842T2 (en) | 2009-04-09 |
JP2006519241A (en) | 2006-08-24 |
EP1599445B1 (en) | 2008-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0308025D0 (en) | Compounds | |
GB0305024D0 (en) | Compounds | |
RS50767B (en) | Piperidine derivatives as nmda receptor antagonists | |
TNSN07018A1 (en) | New 4-benzylidene-piperidin derivatives | |
AU2003222832A1 (en) | Compounds having affinity at 5ht2c receptor and use thereof in therapy | |
RU2002110461A (en) | Quinazoline derivatives and their use as pharmaceutical substances | |
JP2015514770A (en) | Compositions and methods for modulating 15-PGDH activity | |
TN2010000171A1 (en) | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AND THEIR USE AS KINASE K13 KINASE KINASE INHIBITORS | |
WO2005028445A3 (en) | Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain | |
NO20034311L (en) | CCR5 antagonists for the treatment of AIDS | |
GB0128499D0 (en) | Therapeutic agents | |
NO20071008L (en) | Process for the preparation of N-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives | |
EA200800402A1 (en) | DERIVATIVES N- (Arylalkyl) -1H-PYRROLOPYRIDIN-2-CARBOXAMIDES, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY | |
ZA200403334B (en) | Pyrimidine derivatives | |
EA201070010A1 (en) | DERIVATIVES OF 7-ALKINYL-1,8-NAFTYRIDONES, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY | |
NO159794C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 7-SUBSTITUTED THEOPHYLLINE DERIVATIVES. | |
JP2006519798A5 (en) | ||
AU2003232771A1 (en) | N-aryl-4,5-diaminopyrazols and dyes containing said compounds | |
ATE259359T1 (en) | BENZOXAZOLE DERIVATIVES FOR USE AS INTEGRIN INHIBITORS | |
ZA200304908B (en) | Use of pyrazolo[4,3-D]pyrimidines. | |
JP2006519241A5 (en) | ||
WO2005109987A3 (en) | 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | |
NO20041704L (en) | Substituted alkylaminopyridazinone derivatives, processes for their preparation and pharmaceutical compositions containing them | |
GB0106419D0 (en) | Novel compounds | |
AU2003233793A1 (en) | Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |